Clinical trials: Malaria Vaccines
Falciparum Malaria
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
This is a phase Ib double-blind randomized placebo controlled age-deescalating trial to assess sagety and immunogenicity of two virosome formulated anti-malaria vaccine components (PEV 301 and PEV 302) administered in combination…
- Trial name
- PMAL03 (NCT00513669)
- Testing
- PEV 301& 302 in virosomes, Inflexal V (active comparator)
- Where
- Tanzania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
This study is a single site, randomized, double-blind, placebo-controlled trial. The trial will assess the safety, tolerability, immunogenicity and vaccine efficacy (VE) of PfSPZ Vaccine in Gabonese children that are naturally…
- Trial name
- NCT03521973
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Gabon
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali
Background: Malaria is a disease spread by mosquitos. Pregnant women are highly susceptible to malaria. This can lead to poor health outcomes for pregnant women and their babies.
- Trial name
- NCT03989102
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 324 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum, Feasibility
Malaria Vaccine Pilot Evaluation
The RTS,S/AS01 malaria vaccine is being introduced sub-nationally in phased pilot introductions through the EPI programmes in Malawi Ghana and Kenya.
- Conditions
- Malaria,Falciparum, Feasibility, Safety, Mortality
- Trial name
- MVPE (NCT03806465)
- Testing
- Feasibility survey, Sentinel hospital surveillance, Community mortality surveillance
- Where
- 3 sites in Ghana, Kenya and 1 more
- Volunteers
- 30,124 people, healthy volunteers welcome
- Sponsor
- Rafiq OKINE
Malaria
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.
Malaria is an important cause of death and serious illness among Mozambican children. Although the risk of malaria can be reduced by drugs and by impregnated bed nets, it would be helpful if children could be protected against…
- Trial name
- NCT00197041
- Testing
- RTS,S/AS02A
- Where
- Mozambique
- Volunteers
- 2,022 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine
The RTS,S/AS02A vaccine (or GSK 257049 vaccine), GSK Biologicals' candidate Plasmodium falciparum (P. falciparum) malaria vaccine is being developed for the routine immunization of infants and children living in malaria endemic…
- Trial name
- NCT00323622
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix™-B, Hiberix®
- Where
- Mozambique
- Volunteers
- 1,737 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Baseline Cohort Malaria Morbidity Study
The BLOOMy study is a longitudinal prospective cohort study of healthy children to assess the incidence of clinical malaria over the main transmission season.
- Trial name
- BLOOMy (NCT04601714)
- Where
- Burkina Faso
- Volunteers
- 459 people
- Sponsor
- Groupe de Recherche Action en Sante
Malaria, Malaria Infection
Malaria Vaccine for Children in Mali
This study will evaluate the safety and immune response of children to an experimental malaria vaccine called AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909.
- Trial name
- NCT00740090
- Testing
- AMA1-C1/Alhydrogel plus CPG 7909
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
This clinical trial aims to learn about the safety and immunogenicity of the blood-stage malaria vaccine candidate SUM-101 in infants and children, paving the way for its incorporation into a multi-stage malaria vaccine.
- Trial name
- SUM-101 (NCT06618885)
- Testing
- SUM-101
- Where
- Burkina Faso
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Malaria, Falciparum
Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
This trial is currently evaluating one candidate malaria vaccine, FMP1/AS02A. This candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00223990
- Testing
- FMP1/AS02A, RabAvert
- Where
- Kenya
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI…
- Trial name
- NCT05155579
- Testing
- R21/Matrix-M - single vial formulation, R21/Matrix-M - two vial formulation, Licensed vaccine - Measles-rubella
- Where
- 2 sites in Mali, United Kingdom
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Intermittent Preventive Treatment in Infant in Mali
Studies have shown that Intermittent preventive treatment in infants (IPTi) with Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to EPI vaccines.
- Trial name
- NCT00766662
- Testing
- Sulfadoxine pyrimethamine
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Bamako
Plasmodium Falciparum Malaria
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in malaria-exposed children living in western Kenya and aged 12-47 months
- Trial name
- NCT00317473
- Testing
- FMP1/AS02A Malaria vaccine, Imovax Rabies vaccine
- Where
- Kenya
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.
GSK Biologicals is developing in partnership with the Malaria Vaccine Initiative at PATH a candidate malaria vaccine RTS,S/AS02 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00197067
- Testing
- RTS,S/AS02D and RTS,S/AS02A
- Where
- Mozambique
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial
Malaria is one of the leading causes of deaths in children below five years old. Despite antimalarial drugs and insecticide treated bed nets, the established means of treatment and protection, malaria still continues to affect…
- Trial name
- MAL059 (NCT00872963)
- Testing
- RTS,S/AS01E
- Where
- Kenya
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Malaria
Seasonal R21 Mass Vaccination for Malaria Elimination
This is a cluster randomized trial to determine the impact of seasonal R21/MM mass vaccination (all ages) on malaria transmission and morbidity.
- Trial name
- SERVAL (NCT06578572)
- Testing
- R21Matrix M
- Where
- 2 sites in Burkina Faso, The Gambia
- Volunteers
- 16,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Malaria Vaccine in Children in Mali
This study will test an experimental vaccine called AMA1-C1 in children to see if it is safe and if it reduces episodes of malaria parasitemia (parasites in the blood) in children exposed to malaria.
- Trial name
- NCT00341250
- Testing
- AMA1-C1/Alhydrogel Malaria Vaccine
- Where
- 2 sites in Mali
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and…
- Trial name
- VAC093 (NCT06958198)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
The purpose of this pre-licensure cohort study was to estimate the incidence of adverse events of special interest (AESI), other adverse events (AE) leading to hospitalisation or death, meningitis and malaria in sub-Saharan…
- Trial name
- NCT02374450
- Testing
- Blood collection
- Where
- 5 sites in Burkina Faso, Ghana and 1 more
- Volunteers
- 36,366 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
This study will be conducted in Siaya County in Nyanza Province, western Kenya. Healthy children aged 5 months through 9 years of age living within approximately 10 km of the study clinic(s) (Siaya County Referral Hospital, or…
- Trial name
- NCT02687373
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Kenya
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.